Purple Biotech Bringing Hope to Pancreatic Cancer Patients
Purple Biotech (Nasdaq: PPBT) has completed a Phase 1 dose escalation study of CM24, reporting encouraging overall survival data in third line pancreatic ductal carcinoma (PDAC) patients.
Purple is now enrolling patients in a randomized Phase 2 trial that will be conducted in collaboration with Bristol Myers Squibb. The company expects to report initial Phase 2 data by the end of 2023.
Highlights
In the dose escalation portion of the study, 11 refractory PDAC patients whose cancer progressed following two lines of prior therapies, were treated with CM24 in combination with nivolumab.
Based on the study’s safety, tolerability, efficacy, pharmacokinetic and pharmacodynamic data, the recommended Phase 2 dose of CM24 in combination with nivolumab was determined to be 20mg/kg.
The company’s Phase 2 randomized study of CM24 in combination with nivolumab and standard of care chemotherapy vs. standard of care chemotherapy alone,
Purple’s investigational immunotherapy combination was well tolerated across all dose levels with no recorded Drug Limiting Toxicities.
CM24 is a humanized monoclonal antibody that blocks CEACAM1, an immune checkpoint protein that supports tumor immune evasion and survival, through multiple pathways.
About Purple Biotech
Purple Biotech Ltd. is a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The Company’s corporate headquarters are located in Rehovot, Israel. For more information, please visit https://purple-biotech.com/.
